

Review

Not peer-reviewed version

Nutrition and Physical Activity as Modulators of Osteosarcopenic Adiposity: A Scoping Review and Recommendations for Future Research

[Vesna Vucic](#) , [Danijela Ristic Medic](#) , [Aleksandra Arsic](#) , [Snjezana Petrovic](#) , [Marija Paunovic](#) , [Nadja Vasiljevic](#) , [Jasminka Z. Ilich](#) *

Posted Date: 3 March 2023

doi: 10.20944/preprints202303.0057.v1

Keywords: osteosarcopenic adiposity; osteosarcopenic obesity; nutrients; nutritional status; physical activity; resistance training



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article

Nutrition and Physical Activity as Modulators of Osteosarcopenic Adiposity: A Scoping Review and Recommendations for Future Research

Vesna Vucic ¹, Danijela Ristic Medic ¹, Aleksandra Arsic ¹, Snjezana Petrovic ¹, Marija Paunovic ¹, Nadja Vasiljevic ² and Jasminka Z. Ilich ^{3,*}

¹ Group for Nutritional Biochemistry and Dietology, Centre of Research Excellence in Nutrition and Metabolism, Institute for Medical Research, National Institute of Republic of Serbia, University of Belgrade, Belgrade, Serbia; vesna.vucic@imi.bg.ac.rs; dristicmedic@gmail.com; aleksandraarsicimi@gmail.com; snjezana.petrovic@imi.bg.ac.rs; marija.paunovic@imi.bg.ac.rs

² Institute of Hygiene and Medical Ecology, Medical Faculty University of Belgrade, Belgrade, Serbia; nadja.vasiljevic@med.bg.ac.rs

³ Institute for Successful Longevity, Florida State University, Tallahassee, FL, USA

* Jasminka Z. Ilich, Institute for Successful Longevity, Florida State University, Tallahassee, FL 32306, USA. jilichernst@fsu.edu .

Abstract: Osteosarcopenic adiposity (OSA) syndrome denotes the confluence of bone, muscle, and adipose tissue deterioration. Being a complex entity, numerous uncertainties about OSA still exist, despite the extensive research on the topic. Our objectives were to evaluate human studies addressing dietary intake/nutritional status, and the quantity/types of physical activity related to OSA. The search in PubMed, Scopus, and Web of Science databases was conducted to examine relevant articles published from inception to the end of December 2022, utilizing the MeSH strings in the search strategy. Only studies published in English and conducted in humans (≥ 18 years) without chronic conditions (cancers, kidney/liver disease) or pregnancy, were used. Book chapters, abstracts-only, and studies in which participants did not have all three body composition components measured to identify OSA, or when body composition components could not be related to the independent/exposure variables were excluded. A total of $n = 1020$ articles were retrieved from all three databases and eight more from the reference lists. After exclusion of duplicates and other unsuitable articles, $n = 23$ studies were evaluated. Among those, eleven were from epidemiological or cross-sectional studies relating nutrients/dietary intake or nutritional status with OSA. Another four examined the relationship between serum biomarkers (vitamin D and ferritin) with OSA, while eight articles presented the results of the interventional studies with resistance training. Overall, higher protein, calcium, potassium, and vitamins D and C intakes emerged as nutrients positively modifying OSA, along with diet higher in fruits and low-fat dairy foods. Higher serum vitamin D and ferritin were respectively positively and negatively related to OSA. Resistance training was a safe intervention yielding several beneficial outcomes for the OSA syndrome in older women.

Keywords: osteosarcopenic adiposity; osteosarcopenic obesity; nutrients; nutritional status; physical activity; resistance training

1. Introduction

Osteosarcopenic adiposity (OSA) syndrome also known as osteosarcopenic obesity (OSO) is the most advanced stage on the spectrum of body composition disorders. Its first identification and proof of concept has been established in 2014 [1]. Briefly OSA is a condition with simultaneous deterioration of bone (osteopenia/osteoporosis) and muscle (sarcopenia/dynapenia) with increased presence of body fat (adipose tissue). Body fat may be manifested as an apparent overweight/obesity, or as a redistributed fat around organ tissues (visceral) and/or as an infiltrated fat (ectopic) into bone, muscle

and other organs [2]. The original term osteosarcopenic obesity was adjusted to osteosarcopenic adiposity [2] to better reflect the heterogeneity of fat tissue (subcutaneous, visceral, ectopic), as well as the nature of different adipocytes (white, beige, brown). In addition, the obesity in general terms typically refers to overweight, most often defined by high body mass index (BMI) despite that the inadequacies of BMI for characterizing the body composition phenotypes and its paradoxical relations to morbidity/mortality have been widely recognized [2–5].

OSA concept was substantiated based on several established constructs characteristic for each of the three body composition tissues (bone, muscle, fat) [1,2] including: 1) Common precursors in the mesenchymal stem cells (osteoblasts, myocytes, adipocytes) and their deregulation leading to osteopenia/osteoporosis, sarcopenia/dynapenia, and compromised adipose tissue, 2) Hormonal interactions among three tissues (e.g., osteocalcin and sclerostin released from bone cells; myostatins and troponins released from muscle cells; estrogens and adipokines released from adipocytes), 3) Common etiologies of the impairment of each tissue; from lifestyle (overnutrition/malnutrition, lack of physical activity), to low-grade chronic inflammation, to changes in hormonal levels, to neuromuscular disfunction, 4) Aging and all accompanied inevitable changes, 5) Easily observed deterioration in body composition phenotypes with the ensuing medical diagnoses [1,2,6–9]. Figure 1 depicts the OSA/OSO conceptualization as a body tissue triad.




Figure 1. Osteosarcopenic adiposity/obesity and its components. Adapted from Ilich et.al. [1].

Since its conception, OSA has been studied across the world in diverse populations and with different methods/techniques and cutoffs criteria used for its identifications. As a result, no unique methodology has been identified and the wide range of prevalence rates has been reported. So far, it has been associated with functional disabilities, increased frailty and risk of falls, systemic metabolic deregulation and multiple chronic conditions [2,7]. Additionally, based on the characteristics of the syndrome, OSA may be associated with poor overall nutrition or inadequate intake of certain nutrients, as well as with a low engagement in physical activities of any kind [10,11]. However, no in-depth evaluation of such studies has been done, other than a small meta-analysis analyzing four studies that examined resistance training intervention effects on body composition and physical function in elderly OSA participants [12].

Therefore, because of the numerous uncertainties about OSA syndrome, the specific objectives of this scoping review were to evaluate the studies in human subjects addressing dietary intake and nutritional status, as well as the quantity and type of physical activity related to the syndrome. Additionally, we noted the prevalence of OSA, addressed the lack of common diagnostic criteria and identified other gaps in current research, as well as highlighted the areas requiring further research. Nonetheless, the overall goal was to stimulate the launch of interventional clinical trials (currently lacking) that could lead to a better understanding of the processes within, as well as uncover the prevention and management strategies for OSA. The OSA and OSO terms and abbreviations (as well as osteopenic obesity/adiposity and sarcopenic obesity/adiposity) are used here interchangeably and follow those used in the original papers discussed.

2. Methods

2.1. Search strategy

The search in PubMed, Scopus, and Web of Science databases was conducted to examine relevant articles published from inception to the end of December 2022. In the search strategies (strings adapted when necessary to fit the specific search requirements of each database), the following keywords and terms were used: Medical Subject Headings (MeSH) terms were used in the search strategy: ALL FIELDS osteoporotic OR osteosarcopenia OR osteopenia OR osteoporosis AND sarcopenia OR sarcopenic OR dynapenia AND obesity OR adiposity AND body fat OR bone mineral density, OR ALL FIELDS osteosarcopenic obesity OR osteosarcopenic adiposity, AND ALL FIELDS fractures OR fracture risk, AND ALL FIELDS nutrition OR nutrients OR physical activity, AND ALL FIELDS adults OR elderly OR postmenopausal women, NOT ALL FIELDS animal. Additionally, in order not to miss relevant articles, the reference lists of the related articles and reviews were examined as well as the relevant articles found to be in-press or just published (January 2023) after the search was completed.

2.2. Eligibility criteria

Only studies conducted in humans (≥ 18 years) and published in English language were used and no time limitation was applied. Based on the above criteria, co-authors screened the titles and abstracts and selected the eligible articles. Subsequently, potentially eligible full-text articles were downloaded and, after duplicates were removed, extracted and reviewed independently by the five co-authors (V.V., D.R.M., A.A., S.P., and M.P.) with 10% of double checking. Book chapters, conference abstracts or abstracts-only, letters, articles with unusable information, and those conducted in children and adolescents, pregnant women, as well as those in animal models and cell cultures were excluded, as well as the studies in populations having chronic conditions (e.g., cancers, kidney/liver disease, HIV, or thyroid, glucocorticoid medication use). In addition, studies in which participants did not have all three body composition components (bone, muscle/lean and fat tissues) measured to identify OSA, or when all three body composition components could not be related to the independent/exposure variables (nutrition and physical activity), or when participants had only osteoporosis, or sarcopenia, or obesity, were excluded as well. The final set of articles was selected (by J.Z.I) based on the following inclusion criteria: 1) observational and/or epidemiological studies, 2) clinical trials with nutrition and or physical activity intervention, 3) studies that considered nutrition, nutritional status, and/or physical activity as independent/exposure variables, 4) studies that included nutritional and/or physical activity biomarkers in blood/urine as independent/exposure variables. Any disagreement was settled by consensus among all authors.

2.3. Data extraction

The following information was extracted from the included articles and presented in the tables: Name of the first author, publication year, search topic; Country and setting; Study design and duration of follow-up or intervention when applicable; Diagnostic criteria for each condition (osteopenia/osteoporosis, sarcopenia/dynapenia, adiposity); Sample size and sex of participants; Age range or mean age at baseline and follow-up, and/or mean age of participants with OSA/OSO; Prevalence/incident cases of OSA/OSO; Assessment tools used for identification of OSA/OSO, dietary intake or physical activity and/or lab analyses; Comparison of OSA/OSO participants with those having one or more body composition impairments (e.g., osteopenia/osteoporosis, osteopenic obesity osteosarcopenia, sarcopenia, sarcopenic obesity, obesity/adiposity alone) or normal.

3. Results

A total of $n = 1020$ articles were retrieved in the initial search from all three databases and eight more from the reference lists. After exclusion of duplicates ($n = 81$), a total of $n = 947$ articles were screened and, $n = 187$ were fully assessed. Of those, $n = 166$ were excluded for various reasons (mostly

for not having reported the values of all three-body composition tissues to identify OSA, or inability to relate independent variables to the outcomes). Two papers published after the search was completed, were also included in this review. Finally, $n = 23$ articles were included and evaluated in this scoping review. Figure 2 presents the flowchart (PRISMA) of the study selection process. Of note is that all studies are relatively new, the earliest one being from 2017 [13]. This is understandable considering that OSA/OSO was identified just some 10 years ago, and the proof of concept was published in 2014 [1]. In the years prior, each of the body composition compartments was studied separately, or at the most as a combination of two impaired tissues (most often sarcopenia and adiposity, as sarcopenic obesity) [1].




Figure 2. Flowchart (PRISMA) of the study selection process.

3.1. Dietary intake, nutritional status and OSA

Table 1 presents characteristics and results of studies with dietary intake or nutritional status as independent/exposure variables related to OSA/OSO. Of the eleven studies in this section, eight were either cross-sectional or observational, examining the relationship between OSA and nutritional

status of the participants or their overall dietary intake, and/or intake of specific nutrients [13–20]. Three of them also evaluated engagement in physical activity or sedentary lifestyle [16,17,19]. In addition, one study was the 6-month randomized clinical trial investigating the effects of weight loss and dairy foods and/or calcium/vitamin D supplements on body composition [21], followed by the subsequent secondary analysis evaluating the cardiometabolic risk factors as the outcomes of the same intervention [22]. The only prospective study followed the participants for 5 and 10 years examining the influence of energy-adjusted dietary inflammatory index (E-DII) on body composition and fracture rates [23]. A total number of evaluated participants was $n = 19,151$ (at baseline) with $n = 12,143$ (63.4%) women. The average age of the participants was 66.3 years, ranging from 50 to 95.2 years, with women being slightly older than men. The highest prevalence of OSA/OSO (when reported separately in women and men), was 91.9% in women [17] and 53.3% in men [15]. The lowest prevalence in women and men (reported as combined) was 6.4% [19]. The studies were conducted on five continents: Europe (Croatia)[14,15], the U.S.[21,22], Asia (South Korea) [13,16–18,20], South America (Brazil) [19] and Australia [23]. See Table 1.

Table 1. Characteristics and results of studies with dietary intake and/or nutritional status as independent variables related to osteosarcopenic adiposity/obesity (OSA/OSO1).

Reference, Studied topic	Country Setting	Study Design	Diagnostic criteria & Instruments			Sample size, <i>n</i> (%)	Age (years)	OSA/OS O Prevalence ² <i>n</i> (%)	Assessment Tools	Compared to ³	Outcomes in OSA/OSO group (or others if indicated)	
			Bone	Lean/Muscle	Adipose							
Cvijetic, S, 2023 [14], Nutritional status in nursing homes residents during COVID	Croatia, Six Nursing Homes	C-S Inclus/Exclusion criteria applied	T-score ≤-1 for total bone mass With BIA-ACC	S-score ≤-1 With BIA-ACC	BF%: F ≥32; M ≥25 With BIA-ACC	Total, <i>n</i> =365; F, <i>n</i> =296 (81); M, <i>n</i> =69 (18.9)	Mean, F, 84.3 M, 83.1	Total, <i>n</i> =242 (66.3); F, <i>n</i> =209 (70.8); M, <i>n</i> =33 (47.8)	BIA-ACC BioTekna® Mini Nutritional Assessment (MNA); Other questionnaires	Normal; Others, combination of osteoporosis and/or sarcopenia and/or obesity alone	-32.4% and 31.3% of F and M were at risk for malnutrition and 5.8% and 6.2% of F and M, respectively were malnourished; -No difference in malnourishment or risk of it in those with or without OSA; -No difference in OSA	and

prevalence or nutritional status in those with or without COVID; -Lower phase angle (indicating lower cell integrity and muscle quality); -Lower total bone mass; -Higher intramuscular adipose tissue

Keser, I, 2021 [15]	Croatia, Nursing Home	C-S Inlus/Exclusion criteria applied	T-score \leq -1 for total bone mass With BIA-ACC	S-score \leq -1 With BIA-ACC	BF%: F \geq 32; M \geq 25 With BIA-ACC	Total, n=84; F, n=69 (82); M, n=15 (18)	Mean 83.5 Range 65.3-95.2	Total, n=45 (53.6); F, n=37 (53.6); M, n=8 (53.3)	BIA-ACC BioTekna® 24-h recall; Other questionnai res	Osteopenic adiposity, adiposity alone	-Lower trend for protein, omega-3, fiber, Ca, Mg, K, vitamins D and K intake; -All participants consumed
----------------------------	-----------------------	--------------------------------------	--	--------------------------------	--	---	---------------------------	---	--	---------------------------------------	--

home residents													nutrients below recommendations; -Signif. higher extracellular water, indicating higher inflammation
NoP JZ,* 2019 [21] Weight loss with low fat dairy foods and calcium/vitamin D supplements effects on bone and body composition	United States, Community dwelling Caucasian, overweight/obese postmenopausal women	Inclus/Exclusion Criteria applied; 6-month intervention with 3 randomized groups (dairy, suppl., placebo); All samples blinded for analysis	T-score ≤-1 for hip and/or spine for osteopenia (no osteoporosis) With iDXA	Total lean mass (kg); Android lean (kg) Gynoid lean (kg) With iDXA	BF%: Average at baseline 45.9 With iDXA	At baseline with complete data, n=135 (dairy, n=64, Ca/vitD suppl., n=62, placebo, n=62); At 6-month, n=97 (dairy,	Mean 55.8 at baseline; 6.6 years since menopause	Not reported; All three body composition components were measured and evaluated at baseline and after 6 months of	iDXA; Routine lab equipment and ELISA (for blood and urine samples; 3-day dietary records; Activity records	Baseline values; Groups after 6 months of intervention	-All participants lost ~4%, ~3%, and ~2% body weight, fat, and lean mass, respectively; -Dairy group: signif. higher loss in waist, hip, and abdominal circumference and body fat (total, android); signif. lower		

	n=32, Ca/vitD suppl., n=37, placebo, n=30); Moderate energy restriction (85% of total energy needs) to all participan ts Dropout: 28.2%; Imputed analyses for missing data	interventi on	loss in lean mass (total, android); <u>-Supplement group</u> : signif. lower decrease in total body, spine, radius BMD; signif. increase in femoral neck and total femur BMD <u>-All participants</u> improved in (due to weight loss): cardiometabol ic indices (BP, TC, triglycerides, insulin, leptin, adiponectin, ApoA1, ApoB)
--	--	------------------	--

NoP
Ilich,
JZ,* 2022
[22];
Secondary
analysis to
Ilich, JZ
2019 [21]
Weight
loss with
low-fat
dairy
foods and
calcium/

vitamin D
suppleme
nts effects
on cardio-
metabolic
risk

-Dairy group:
Signif.
decrease in BP,
TC, LDL-C,
TC/HDL-C,
ApoB, leptin;
signif. increase
in
adiponectin,
ApoA1
-Supplement
group: Signif.
decrease in BP,
triglycerides,
LDL-C, ApoB,
leptin; signif.
increase in
HDL-C,
adiponectin,
ApoA1

^A Choi, M, 2021 [16] Dietary Calcium and phosphoru s intake	S. Korea, KNHANES 2008-2011	C-S Retro- spective Inclus/Exclu sion criteria applied	T-score ≤- 1 for hip and/or spine to include osteopeni a &	SMI F ≤5.4 M ≤7.0 With DXA	BF%: F ≥32; M ≥25 With DXA BMI: kg/m2 overweigh	Total, n=7007; F, n=3864 (55.1); M, n=3143 (44.9)	Mean, 62.3 OSA- 65.5; More wome n	Total, n=763 (10.9) F and M combine d	DXA 24-h recall	Total of 8 groups: Normal and combinations: osteoporosis, and/or sarcopenia and/or obesity alone	-Lower calcium intake signif. associated with osteosarcopen ia and OSA;
--	-----------------------------------	--	--	-------------------------------------	---	--	---	--	--------------------	--	---

					osteoporosis With DXA	t ≥23<25, obese ≥25	(68.4%)					-Lower phosphorus intake signif. associated with sarcopenic adiposity; - Ca/P ratio (below median) signif. associated with osteopenic adiposity -Signif. lower activity in OSA compared to normal group
^A Choi, M, 2020 [17] Protein intake: total and plant-based	S. Korea, KNHANES 2008-2009	C-S Retro-spective Inclusion/Exclusion criteria applied	T-score ≤-1 for hip and/or spine to include osteopenia &	ALM/Weight <1SD of Korean reference population	BF%: F ≥32; M ≥25 With DXA BMI: kg/m2 overweigh	Total, n=1351; F, n=706; M, n=645	Mean 60.5; F-OSA 65.5 M-OSA 63.8	Total, n=865 (64.0); F, n=649 (91.9); M, n=216 (33.4)	DXA 24-h recall	Normal, only; No other groups were considered	-M >65 y consuming <0.91 g/kg of protein (Korean recommend.) had 5.8 higher	

osteoporosis (20-39 y old) With DXA t $\geq 23 < 25$, obese ≥ 25 With DXA odds of developing OSO; -Plant-based protein intake in M-OSO was higher than in M-normal. -Energy consumption in M-OSA higher than in M-normal. -Signif. lower intense physical activity in M-OSO

Bae, Y-J, 2020 [18]	S. Korea KNHANES 2008- 2010	C-S Retro- spective Inclus/Exclu sion criteria applied	T-score \leq - 1 for hip and/or spine to include osteopeni a & osteoporo sis	ALM/wei ght <1SD of reference populatio n	Waist circumfere nce ≥ 85 cm	Total, n=1420 F only	Range 50-64; OSO 58	n=194 (13.7)	DXA, 24-h recall	Normal; osteopenia/ osteoporosi; sarcopenia; and/or obesity	-Signif. lower intake of potassium and vitamin C; - Signif. lower intake of fruits rich in vitamin C and potassium
----------------------------	-----------------------------------	--	--	--	---	----------------------------	------------------------------	-----------------	---------------------	---	--

With DXA											
^A de Franca, NAG, 2020 [19]	Brazil; Community dwelling; Health Survey of the City of São Paulo. (ISA-Capital 2015) (2015 ISA-Nutrition)	C-S Inclus/Exclusion criteria applied	T-score ≤-1 for hip and/or spine to include osteopenia and osteoporosis With DXA	ALM/BMI F <0.512 M <0.789 With DXA	FMI M >9 kg/m ² ; F >13 kg/m ² with DXA	Total, n=218; F, n=113 M, n=105 (48); older adults, n=161 (74)	Mean 63; Range 59–69	Total, n=14 (6.4) F and M combine d	DXA 24-h recall; Handgrip with Jamar® dynamometer; Gait speed usual pace, 4 m/min	Normal + 6 groups: osteopenia/osteoporosis; sarcopenia; obesity; osteopenic sarcopenia; osteopenic obesity sarcopenic obesity	- Signif. lower protein intake (g/kg/Wt) but not as % of energy; -None of other nutrients were signif. different among groups; - Signif. lower grip strength and more time spent sitting
^{NoP} Cervo, MM, 2020 [23]	Australia: Population-based community dwelling; Southern Tasmania, TASOAC 2002-2004	Prospective; with follow-up at 5 and 10 years; Inclus/Exclusion criteria applied	Changes in T-score ≤-1 for hip and/or spine to include osteopenia & osteoporosis;	Changes in ALM whole-body DXA; Hand grip strength; Knee extension; fall risks	Baseline BF%: F ~40 M ~28 With whole-body DXA BMI kg/m ² : F ~28 M ~27.7	Total at baseline, n=1098: F, n=562 M, n=536 At 5 years, n=768;	Mean at baseline: 63; Range 51-79	Not reported; For every unit increase in E-DII score, Incidence fracture increased	DXA, FFQ to calculate E-DII scores; Dynamometers for changes in grip strength and knee	With baseline values and changes at five and 10 years of follow-up	-Consumption of pro-inflammatory diet (higher E-DII scores), increased incidence of fractures over 10 years in M, but not in F,

					With DXA			At 10 years, n=566		9% in M but decrease d 12% in F	extension; PPA for changes in fall risk; Self -assessment questionnaires for fractures		despite being associated with reductions in lumbar spine and total hip BMD in both sexes; -E-DII scores signif. associated with higher fall risk scores and lower ALM in M but not in F.
Park 2018 Dietary inflammatory index (DII); Higher scores denote higher proinflam	S, S. Korea, C-S	[20] KNHANES, 2009-2011	Retro-spective Inlus/Exclu sion criteria applied	T-score ≤-1 for hip and/or spine to include osteopeni a & osteoporo sis; With DXA	ALM/wei ght <1SD of reference populatio n; with DXA	BMI: kg/m2 based on Asian-Pacific guidelines overweight ≥23<25, obese ≥25	Total, n=1344 F only	Mean 62.3; OSO 64	Total, n=455 (31.8)	DXA, 24-h recall, DII score	Normal, osteosarco-penia, osteopenic obesity, sarcopenic obesity	-DII scores signif. associated with higher risk for OSO; -Groups with osteosarcopen ia, osteopenic obesity, sarcopenic obesity had	

ma-tory diet											signif. lower intake of vitamins C and E compared to the normal group
Kim J, 2017 [13] Diet Quality-Index-International (DQI-I); higher scores denote better food quality intake	S. Korea KNHANES 2008-2010	C-S Retro-spective Inclus/Exclusion criteria applied	T-score ≤-1 (for Asian reference population) With DXA	ALM/Wei ght <1SD of Korean reference population (20-39 y old) With DXA	BF% ≥40 of body fat by gender With DXA	Total, n=6129; F, n=3550; M, n=2579	F 61.9; M 60.8; OSO F 64.3; OSO M 64.2	F 25%; M 13.5%	DXA, 24-h recall,	Healthy Korean adults aged 20–39 years	-In F: Higher scores on the DQI-I associated with better body composition phenotypes; -Signif. less intake of fish, mushrooms, milk, energy, protein -Tendency of less frequent consumption of meat, eggs; -In M: DQI-I scores were not associated

with body
composition
abnormalities.

¹OSA/OSO terms are used interchangeably and reflect those used in each article. ²Prevalence includes both pre- (with osteopenia and/or presarcopenia) and full OSA/OSO; ³OSA/OSO participants compared to those with one or more body composition impairments (e.g., osteopenia/osteoporosis, osteosarcopenia, sarcopenia, sarcopenic obesity, obesity/adiposity alone), or normal. ^{NoP}Studies not reporting/calculating the prevalence of OSA/OSO, but still analyzing three body composition compartments from which OSA/OSO prevalence and/or its relation to exposure variables could be derived. *Studies with the same population, design, and intervention, but different independent/exposure variables. ^AStudies reporting association with physical activity or sedentary lifestyle, in addition to nutrition. Abbreviations: COVID: coronavirus disease; C-S: cross-sectional; T-score for bone mineral density (BMD g/cm²); BIA-ACC: Bioelectrical Impedance Analysis with BioTekna®; S-score for muscle; BF: Body Fat; F: females; M: males; DXA: Dual Energy Absorptiometry; BMD: Bone Mineral Density; BP: Blood Pressure; TC: Total Cholesterol; ApoA1: Apolipoprotein A1; ApoB: apolipoprotein B; LDL-C: Low Density Lipoprotein Cholesterol; HDL-C: High Density Lipoprotein Cholesterol; KNHANES: Korea National Health and Nutrition Examination Survey; SMI: Skeletal Muscle Index (kg/height²); ALM: Appendicular Lean Mass; BMI: Body Mass Index; FMI: Fat Mass Index (body fat/height²); TASOAC: Tasmanian Older Adult Cohort Study; E-DII score: Dietary Inflammatory Index; FFQ: Food Frequency Questionnaire; PPA: Physical Profile Assessment; DQI-I: Quality Index-International.

The important findings from these studies are described below and are listed in Table 1. Briefly, Cvijetic et. al., [14] study was conducted in several nursing homes revealing that more than 1/3 of participants were at the risk of developing malnutrition and ~6% were already malnourished (based on the Mini Nutritional Assessment), but there was no difference in the risk of malnutrition or malnourishment between those with or without OSA. This study was conducted during the COVID-19 pandemic and also revealed no difference in OSA prevalence or nutritional status in those who had COVID and those who had not have a disease. However, a lower phase angle (indicating lower cell integrity and muscle quality) and a lower bone mass, while a higher intramuscular adipose tissue were all significantly associated with the presence of OSA. Another, although smaller study, conducted in a nursing home utilized 24-h dietary recalls for the assessment of participants' dietary intake. The results showed a lower intake of protein, omega-3 polyunsaturated fatty acids, fiber, calcium, magnesium, potassium, and vitamins D and K -- all below both European and U.S. recommendations [24,25] in all participants. However, those with OSA had significantly higher extracellular water, indicating heightened inflammatory state in that group.

A six-month randomized clinical trial of weight loss employing 25% reduction in energy intake complemented with either 4-5 servings of low-fat dairy foods, or calcium-plus-vitamin D supplements (1500 mg/day and 600 IU/day, respectively), or placebo (control group) revealed improvement in all body composition components [21]. All participants lost weight, but those in dairy group experienced higher loss in fat and smaller loss in lean mass compared to the control group, or the group taking supplements. The group with calcium/vitamin D supplements showed the best improvements in BMD in several skeletal sites, compared to dairy or control groups [21]. Additionally, the subsequent secondary analysis in these participants (same 6-month intervention) showed improvement in blood pressure and numerous other cardiometabolic risk factors with weight loss in all participants, but significantly better in dairy and/or calcium/vitamin D supplements groups [22] (Table 1). Since evaluation of cardiometabolic outcomes was not a goal of this review, they are not discussed further, but just noted as possible additional benefits to body composition and/or OSA.

The only prospective study in this section followed the participant for 5 and 10 years investigating the influence of E-DII on body composition outcomes in a population of Australian women and men (n = 1098 at baseline) [23]. The results revealed that the consumption of pro-inflammatory diet (higher E-DII scores), increased incidence of fractures over 10 years in men, but not in women, despite being associated with reductions in lumbar spine and total hip BMD in both sexes. In addition, higher E-DII scores were significantly associated with higher fall risk and lower appendicular lean mass in men but not in women.

Each of the following five studies [13,16–18,20] utilized the Korea National Health and Nutrition Examination Survey (KNHANES) databases (from different years), to assess the relationship of several nutrients or foods [16–18], or Dietary Inflammatory Index (DII) [20], or Diet Quality Index International (DQI-I) [13] with OSA/OSO.

Among these, three studies [16–18] were published by the same group of researchers who used the KNHANES from 2008-2011, 2008-2009, and 2008-2010, respectively, thus having the advantage of a large sample size (see Table 1). Choi et al., 2021 [16] reported that lower intake of calcium was significantly associated with both osteosarcopenia and OSA, while the physical activity was the lowest in the participants with OSA. In Choi et al. study [17], protein intake below Korean recommendation (~0.9 g/kg body weight) was associated with higher odds of developing OSO in men. Additionally, intake of plant-based protein in men with OSO was higher than in men without (possibly indicating lower protein quality), while the physical activity was significantly lower in men with OSO. No significant associations were noted in women, of whom 91.9% were identified as having OSO. Bae et al [18] examined intake of fruits, particularly those rich in vitamin C and potassium, in women only. They found that lower intake of potassium and vitamin C and/or lower intake of fruits was significantly associated with OSO. Kim et al., and Park et al. [13,20] used KHANES from 2009-2011 and 2008-2010, respectively. The latter found that the higher DII scores (denoting higher proinflammatory diet) were significantly associated with the OSO phenotype [20],

while the former study examining the DQI-I (higher scores denote better food quality), reported a significantly better body composition with higher DQI-I scores [13]. A small study conducted in Brazilian community dwelling women and men, reported significant association of lower protein intake (g/kg/weight, but not as percentage of energy) in participants with OSO (women and men combined), while none of the other nutrients were significantly different among groups. The participants with OSO also had significantly lower grip strength and preferred more sedentary lifestyle [19].

3.2. Serum nutritional biomarkers and OSA/OSO

A set of four evaluated studies reported the relationship between nutritional serum biomarkers, namely serum ferritin and 25(OH)D, and OSO [26–29] presented in Table 2. One study was derived from a Korean cohort of the Kangbuk Samsung Health Study [26], one from the China's community dwelling women and men [27] and two from the KNHANES databases [28,29]. A total number of evaluated participants was $n = 39,227$ with $n = 25,427$ (64.8%) women. The average age of the participants was 63.1 years (women 62.9 and men 65.4 years). The highest prevalence of OSO was 40.1% and 28.1% in women and men, respectively [28]. The lowest prevalence was 6.4% and 9.4% in women and men, respectively [26] (Table 2).

Chung et al. [26] examined sex-specific serum ferritin concentration in relation to OSO, reporting that women in the highest ferritin tertiles had the highest OSO prevalence. Additionally, higher serum ferritin concentrations were significantly associated with other adverse body composition impairments in women but not in men. The following three studies [27–29] investigated the association of serum 25(OH)D (calcidiol) with OSO phenotype, comparing it with other impairments, namely, osteopenic obesity, sarcopenic obesity, and obesity-only, revealing its supporting role in pathogenesis of the conditions. Ma Y. et al. [27] examined a large sample of Chinese citizens dividing them into groups based on the body composition impairments and tertiles of serum 25(OH)D. They found that the serum 25(OH)D deficiency was associated with greater likelihood of having OSO. The results also revealed the independent negative dose-response associations of 25(OH)D with OSO and other impaired body composition components. The two studies [28,29] showed respectively, that vitamin D deficiency/inadequacy was significantly higher in both women and men with OSO compared to other groups and that higher 25(OH)D was associated with significantly lower odds of having adverse body composition features, especially OSO. Additionally, Kim, Y.M. et al., [28] reported that both women and men in OSO group engaged in the lowest physical activity, compared with those belonging to other groups. Please see Table 2.

Table 2. Characteristics and results of studies with serum nutritional biomarkers as independent variables related to osteosarcopenic adiposity/obesity (OSA/OSO¹).

Reference, Studied topic	Country Setting	Study Design	Diagnostic criteria & Instruments			Sample size (%)	Age (years)	OSA/OSO Prevalence (%)	Assessment Tools	Compared to ³	Outcomes in OSA/OSO group (or others if indicated)
			Bone Adipose		Lean/Muscle						
Chung, S-J, 2022 [26] Serum ferritin; Subjects stratified by serum ferritin tertiles	S. Korea, Medical health screening and check-up	C-S Two-center; Inclus/Exclusion criteria applied	T-score ≤-1 for hip and/or spine to include osteopenia & osteoporosis; With DXA	SMI <1SD of reference population; With BIA	BF%: F ≥35; M ≥25 With DXA	Total, n=25,546 ; F, n=16,912 ; M, n=8634	Mean 58.7; F, 58.3; M, 59.6; F-OSO 66.3; M-OSO 67.7	Total, 7.9%; F, 6.4%; M, 9.4%	DXA; InBody-720; Cobas 8000 (for ferritin), Roche Diagnostics	Normal; combination s: osteoporosis, and/or sarcopenia and/or obesity	-Higher serum ferritin signif. associated with combined adverse body composition in F, but not in M; -F in the highest ferritin tertiles had the highest OSO prevalence

^{NoP} Ma, Y, 2020 [27]	China provinces, (commu- nities)	Nine	C-S Inlus/Exclusio n criteria applied	T-score for and/or spine include osteopenia & osteoporosi s With DXA	≤-1 hip	ALM; <1SD than mean; F 13.9 kg M 20.2 With DXA	BF%: F 36 M 27.5 With whole -body DXA	Total, n=4506; F, n=2905 (64.5); M, n=1601 (33.5)	Mean: 68.1; F, 67.6 M, 68.6	Not reported	DXA; Liquid chromatography –tandem mass spectrometry (for 25(OH)D)	Osteopenic obesity, Sarcopenic obesity, Obesity-only	-25(OHD) deficiency associated with greater likelihood of OSO; - Independent negative dose-response associations of 25(OHD) with OSO and other impaired body composition components
^A Kim, YM, 2019 [28]	S. Korea KNHANES 2008-2011		Retro- spective; Inlus/Exclusio n criteria applied	T-score for and/or spine include osteopenia &	≤-1 hip	ALM/Weig ht <1SD of reference population With DXA	BF%: F ≥35; M ≥ 25	Total, n=3267; F, n=2187; M, n=1080	Mean 64.2; F 63.8; M 64.6; F-OSO 66.3;	Total 36.1%; F, 40.1%; M, 28.1%	DXA; Radioimmuno assay (DiaSorin) with 1470 Wizard γ-counter	Osteopenic obesity, Sarcopenic obesity, Obesity-only	-Both F-OSO and M-OSO had signifi. lower serum 25(OH)D (<20 ng/mL); -Both F and M engaged

osteoporosis	M-OSO	in the lowest physical activity;
With DXA	67.7	-F-OSO had the highest prevalence of hypertension, diabetes and metabolic syndrome

Kim, J, 2017 [29]	S. Korea	C-S	T-score ≤ -1	ALM	BF% ≥ 40	Total, n=5908;	Mean	Total, 19.3%;	DXA;	Osteopenic	-Signif.
Serum 25(OHD)	KNHANES 2008-2010	IV, Retro-Spective; Inclus/Exclusion criteria applied	(for Asian reference population) With DXA	<1SD of ref. population With DXA	body fat by gender	F, n=3423; M, n=2485	F 61.2; M 60.7; F-OSO 64.2; M-OSO 63.9	F, 25%; M, 13.5%	DiaSorin 25(OH)D); 24-h recall	(for obesity, Sarcopenic obesity, Obesity only	higher prevalence of 25(OH)D (<20 ng/mL) in both F and M; -Higher 25(OH)D in mid- and later life signif. associated with reduced

odds of
adverse
body
composition,
leading to
OSA
(stronger in
M)

¹OSA/OSO terms are used interchangeably and reflect those used in each article. ²Prevalence includes both pre- (with osteopenia and/or presarcopenia) and full OSA/OSO; ³OSA/OSO participants compared to those with one or more body composition impairments (e.g., osteopenia/osteoporosis, osteosarcopenia, sarcopenia, sarcopenic obesity, obesity/adiposity alone), or normal. ^{NoP}Studies not reporting/calculating the prevalence of OSA/OSO, but still analyzing three body composition compartments from which OSA/OSO prevalence and/or its relation to exposure variables could be derived. ^AStudies reporting association with physical activity or sedentary lifestyle, in addition to nutrition. C-S: cross-sectional; T-score for bone mineral density (BMD, g/cm²); DXA: Dual Energy Absorptiometry; SMI: Skeletal Muscle Index (kg/height²); BIA-ACC: Bioelectrical Impedance Analysis with BioTekna®; BF: Body Fat; F: females; M: males; 25(OHD): 25-hydroxyvitamin D; ALM: Appendicular Lean Mass; KNHANES: Korea National Health and Nutrition Examination Survey.

3.3. *Physical Activity and OSA*

In Table 3, eight interventional studies [30–37] with resistance training are presented. Among these studies, only one included both women and men and a combination of resistance training with aerobic exercise [35]. A total number of evaluated participants was $n = 182$ with majority being women. The age ranged from 60 to 85 years and all recruited participants were identified as having OSA/OSO as per inclusion criteria (except Cunha et al, [31]). Three of the studies were respectively conducted in the community dwelling individuals in Taiwan [30], Main China [35], and Brazil [31]. The other five papers were published by the same group of researchers from Iran [32–34,36,37], where the results from the same participants engaged in the same 12-week interventional resistance training regimen with the elastic band were analyzed but reported different outcome variables affecting women with OSA/OSO (Table 3).

Table 3. Characteristics and results of studies with physical activity as independent variables related to osteosarcopenic adiposity/obesity (OSA/OSO¹).

Reference, Studied topic	Country Setting	Study Design	Diagnostic Instruments	criteria	&	Sample size (n) AND Interventio n	Age (years)	Prevalence ² n (%)	Assessment Tools	Compared to ³	Outcomes in OSA/OSO group (or others if indicated)
			Bone Adipose	Lean/Muscle							
Lee, Y-H, 2021 [30] Progressive resistance training (peRET) effects on functional performance and body composition	Taiwan, Communit y dwelling women	Inclus/Exclusio n Criteria applied; 12-week intervention with 2 randomized groups; Blinded randomization into groups	T-score ≤ -1 for spine to include osteopenia & osteoporosi s; With DXA	SMI < 5.67 kg/m ² ; AND grip strength < 20 kg; OR gait speed < 0.8 m/s	BF%: ≥ 35	Total, n=27; peRET, n=15; 40 min, three times/w; OR Control, n=12; No dropouts; >85% exercise compliance; Follow-up at 6 months	Mean 70.9; No diff. among groups	All participant s, as per inclusion criteria	DXA; BIA Dynamomete r, Thera- Band®	Baseline values; Control group of OSO women (attended group lectures with educationa l material)	-Signif. increase in BMD and T- score for spine -Signif. improvement in Functional Forward Reach; Timed up- and-go test; Timed chair- rise test; Gait speed; -No change in BF%, and some lean

											tissue parameters; -No sustainable benefits after 6 months follow-up
Shen, LI, 2020 [35] Aerobic exercise and resistance training combined effects on body composition	China, Community dwelling, women and men	Inclus/Exclusion Criteria applied; 12-week intervention with 2 randomized groups; No mention on assessor blinding	T-score ≤ -1 to include osteopenia & osteoporosis; With DXA	SMI F ≤ 5.4 kg/m ² ; M ≤ 7.0 kg/m ²	BF%: F ≥ 35 ; M ≥ 25	Total, n=30; Exercise, n=15; 45-60 min/day, 3 times/w; OR Control, n=15;	>60 No diff. between groups	All participants, as per inclusion criteria	DXA; BIA Dynamometer, Elastic band	Control group of 10 women and men	-Signif. increase in BMD and decrease in BF%; - No change in SMI
NoP Cunha, PM, 2018 [31] Resistance training volume (1 & 3 sets) effects on bone, muscle and body fat	Brazil, Community dwelling, women	Inclus/Exclusion Criteria applied; 12-week intervention with 3	No specific identification for bone, muscle and body fat status. Composite OSO Z-score derived from average of the muscular strength, SMM, % body fat, and BMD components was calculated by			Total, n=62; Intervention groups: 1-set training (n=21, for 15 min); OR	Mean 67.4; No diff. among groups	Not reported	DXA; Repetition Maximum (RM) by chest press, knee extension, preacher curl exercise	Baseline values; Also, 1 set vs. 3 sets of training; Control group	-Signif, increase in total strength; SMM; -Signif improvement in OSO

			randomized groups; Blinded randomization into groups	formula: (muscular strength Z-score)+(SMM Z-score)+(-1xbody fat Z-score)+(BMD Z-score)/4				3-sets (n=20, for 50 min) 3-times/w; OR Control (n=21); ≥85% exercise compliance				Composite Z-score from baseline to-post test -Signif, decrease in body fat; -No change in BMD -Dose response to higher activity (3 sets induced higher improvement than 1 set); -Both sets induced higher improvement compared to control			
Banitalebi, E,* 2020 [34]	Iran, Community dwelling women	Inclus/Exclusion Criteria applied;	T-score for hip and/or spine to include	≤-1 14. 10 m walk test ≤ 1		BF%: ≥32 BMI: >30	Total, n=63; Progressive Elastic Band resistance	Range 60-80; Mean 64.1	All participants, as per	DXA; Dynamometer Thera-Band®	Control group of 100 women	-Signif. increase in handgrip strength,			

training effects on body composition, functionality, various OSO biomarkers	12-week intervention with 2 randomized groups; Concealed randomization (based on age and OSO composite Z-scores) into groups; Blood samples blinded for analysis	osteopenia & osteoporosis; With DXA	(m/s); SMI $\leq 28\%$ 15. O R 16. $\leq 7.76 \text{ kg/m}^2$	kg/m ²	training up to 60 min. (3 times/week) , n=32; OR Control, n=31; Intention to treat analysis; 85% exercise compliance; 19% & 29% dropout in exp. and control groups, respectively ; 25% participants reported side effects in first 3 sessions	No difference between groups	inclusion criteria	ELISA for blood tests	timed chair-rise test, muscle quality; -Signif. increase in estradiol and decrease in leptin; -Slight improvement in OSO composite Z-score; -No difference in BMD; BF; SMI; gait speed and timed-up-and-go test -Slight but insignificant improvement in OSO serum and
--	--	-------------------------------------	---	-------------------	---	------------------------------	--------------------	-----------------------	--

Banitalebi, E,*
2021 [32]

Elastic band resistance training effects on OSO

markers,
serum
microRNAs

other
markers;
-Serum
microRNAs
(miR-133 &
miR-206)
changes
correlated
with changes
in FRAX
scores, serum
25(OH)D and
alkaline
phosphatase
-Signif.
decrease in
lipid-
accumulation
product;
Triglyceride-
glucose-BMI
index;
Visceral
adiposity
index;
Atherogenic
index of

Banitalebi, E,*
2023 [33]
Elastic band
resistance
training effects
on
cardiometaboli
c risk factors

Total, n=48;
Training,
n=26
OR
Control,
n=22;
Intention to
treat

analysis;
85%
exercise
compliance

plasma;
Framingham
risk score;
-NO change
in
Triglycerides
;
Triglyceride-
glucose
index;
triglyceride-
glucose-
waist
circumferenc
e index; C-
reactive
protein;
Metabolic
syndrome
severity
score
-Signif.
decrease in
serum miR-
146; total
cholesterol,
LDL

Hashemi, A,*
2020 [36]
Elastic band
resistance
training effects
on vascular

aging, serum
microRNA-146

-Signif.
increase in
HDL;
-NO
difference in
body weight,
BMI, BMD,
C-reactive
protein

Kazemipour,
N* 2022 [37]
Elastic band
resistance
training effects
on insulin
growth factor
(IGF-1),
fibroblast
growth factor
(FGF-2)

-Signif.
increase in
IGF-1 and
FGF-2
NOT
significant:
Relationship
of IGF-1 and
FGF-2 with
BMD
-NO change
in BMD

¹OSA/OSO terms are used interchangeably and reflect those used in each article. ²Prevalence includes both pre- (with osteopenia and/or presarcopenia) and full OSA/OSO; ³OSA/OSO participants compared to those with one or more body composition impairments (e.g., osteopenia/osteoporosis, osteosarcopenia, sarcopenia, sarcopenic obesity, obesity/adiposity alone), or normal. ^{NoP}Studies not reporting/calculating the prevalence of OSA/OSO, but still analyzing three body composition compartments from which OSA/OSO prevalence and/or its relation to exposure variables could be derived. *Studies with the same population, design, and intervention, but different independent/exposure variables. T-score for bone mineral density (BMD g/cm²); DXA: Dual Energy Absorptiometry; SMI: Skeletal Muscle Index (kg/height²); BF: Body Fat; BIA: Bioelectrical Impedance Analysis; F: Female; M: Male; SMM: Skeletal Muscle Mass; BMI: Body Mass Index; ELISA: Enzyme-Linked Immunosorbent Assay; FRAX- score: Fracture Risk Assessment; 25(OH)D: 25 hydroxyvitamin D (calcitonin); LDL: Low Density Lipoproteins; HDL: High Density Lipoproteins.

Overall, each of the papers reported some benefits including improvements in body fat, muscle mass components (even BMD), some of functional performance measure and some biomarkers (see Table 3). More specifically, Lee et al., and Shen et al., [30,35] reported increase in BMD and the former was the only study with a follow-up at 6 months, showing none of the reported benefits were sustained. The study by Cunha et al., [31] is unique as they investigated response to two resistance training regimens (1-set vs. 3-sets) vs. control group and found a dose response with higher activity (3 sets induced higher improvement) and both sets induced higher improvement compared to the control group. The authors did not identify OSA/OSO as such but created composite Z-scores (derived from average of the muscular strength, skeletal muscle mass (SMM), % body fat, and BMD) and noted a significant improvement after the exercise.

A research group from Iran published several papers with the results derived from the same interventional study with elastic band resistance training in $n = 63$ women ($n = 32$, intervention and $n = 31$, control) all having OSA/OSO as per inclusion criteria [32–34,36,37]. The results from their earliest paper revealed significant increase in handgrip strength, timed chair-rise test, muscle quality, slight improvement in OSA/OSO composite Z-score, as well as increase in estradiol and decrease in leptin [34]. In one of these papers [32], serum microRNAs (miR-133 and miR-206) changes correlated with changes in FRAX scores, serum 25(OH)D and alkaline phosphatase. Banitalebi et al., [33] reported improved composite cardiometabolic risk factors (e.g., lipid-accumulation product, triglyceride-glucose-BMI index, visceral adiposity index, atherogenic index of plasma, Framingham risk score). Hashemi et al. [36] (from the same group), reported significant decrease in serum microR-146, total cholesterol and low-density lipoproteins (LDL) and increase in high-density lipoproteins (HDL), while Kazemipour et al., [37] reported significant increase in insulin growth factor (IGF-2), and fibroblast growth factor (FGF-2). However, this intervention did not result in any significant improvement of the body composition components (e.g., BMD, BMI, body fat, skeletal muscle index), or serum biomarkers, like triglycerides and C-reactive protein (Table 3).

4. Discussion

Based on the results of the studies reviewed, the prevalence of OSA/OSO ranged from some 6% to over 90% (see discussion below). Lower intakes of nutrients that emerged as being significantly associated with OSA/OSO (compared to normal or other impaired conditions), were protein, calcium, potassium, vitamins C and D; all being close to our initial hypotheses and earlier recommendations [7,8,10]. As expected, higher DII scores were associated with OSA or poorer body composition phenotypes and the opposite was true for the DQI-I and higher low-fat dairy foods and fruit intake. Regarding serum nutritional biomarkers, 25(OH)D was studied the most, and surfaced as a beneficial mediator for OSA/OSO and other body composition impairments. A study investigating serum ferritin, showed higher values may detrimentally influence body composition (including OSA/OSO) but only in women. On the issue of physical activity, several studies evaluated it as a secondary outcome and reported the lowest engagement in recreational activities among participants with OSA/OSO. However, the promising results were reported from a few interventional studies with resistance training, showing improvement in various OSA markers, namely, body fat, muscle mass components (even BMD), as well as in some of the functional performance measure and a few of the biomarkers (mostly cardiovascular).

It is important to note that all studies were done in older individuals (majority above 60 years of age) when, unfortunately, all components of body composition (bone, muscle, adipose tissues) impairments develop and continue to deteriorate. As it is well recognized, some of the hallmarks of aging are stem cells exhaustion (defaulting to the adipocytes commitment differentiation instead of balancing between osteoclasts, myocytes, and adipocytes), telomere shortening, cellular senescence, mitochondrial dysfunction (all leading to chronic inflammation), genomic instability, epigenetic alterations and deregulated nutrient-sensing [38,39]. Each of these hallmarks, alone or in combination, ultimately steer to body composition deterioration, in addition to other ailments associated with aging [9,40]. Therefore, investigating OSA/OSO (although an overly complex entity) and taking into account the empirical data from the original studies to support hypotheses, can

provide the most comprehensive view of various modifiers simultaneously affecting all three body composition components.

It is disconcerting to note such a high range in OSA/OSO prevalence (about 6% to 90%; see discussion below). These inconsistencies in literature are due to the lack of universally accepted criteria for OSA identification, as well as to the different methods and technologies used to identify it. A long-time agreement exists for the diagnosis of osteopenia/osteoporosis [41] and the revised consensus for sarcopenia diagnosis [42] but not for osteopenic adiposity, sarcopenic adiposity [43] or even adiposity itself [22]. This is unsettling because the inability to determine prevalence of OSA negatively reflects on its clinical relevance and subsequent treatments and management.

4.1. Dietary intake, nutritional status and OSA

Cvijetic et al., and Keser et al., [14,15] studies are interesting as they are the first ones to measure all three body composition compartments (bone, muscle, and fat) with one bioelectrical impedance (BIA) device (BIA-ACC, BioTekna®) to identify OSA. The BIA-ACC, instrument is based on bioelectrical impedance, but unlike other BIA devices, detects the total bone mass (in addition to all soft tissue components and body water). Therefore, its ability to diagnose OSA is quite unique and advantageous due to its simplicity and ease for both patients and researchers. These two studies although not presenting strong relationship between OSA and nutritional status and/or specific nutrients, have another merit as they were conducted in several nursing homes and reported the complete assessment of body composition and nutrient intake/status among the nursing home residents. Other studies revealed similar or even higher presence of malnutrition in nursing homes in different countries [44,45]. In view of the advanced age and constrained living conditions of nursing home residents, it is expected that some of them will be malnourished and have a poor body composition status. However, it is surprising that COVID-19 infection in the Cvijetic et al., [14] study participants did not show any impact on OSA prevalence, weight loss, or nutritional status. This is contrary to the just published study in French nursing homes [46], where those infected with COVID-19 experienced about 5% of weight loss. Due to some other limitations of both studies, e.g., cross-sectional nature, small number of participants in Keser, et al., [15], and inability of BIA-ACC device to distinguish bone mass/quality in different skeletal regions, more studies like this, where OSA can be diagnosed with one instrument (e.g., BIA or DXA) and conducted in critical populations (like nursing home residents), are warranted.

The results of the 6-month clinical trial of weight loss complemented with low-fat dairy foods or calcium/vitamin D supplements, vs. control (placebo group), are clear in showing the improvement of body composition and bone, respectively, despite the relatively moderate weight loss [21]. Numerous studies reported effects of both dairy foods and calcium/vitamin D supplements on various body composition outcomes. For example, regarding the dairy foods and possible mechanisms influencing body composition and weight, several synergistic influential factors have been proposed, including bioactive components (e.g., whey peptides, conjugated linoleic acid, branched chain amino acids), in addition to calcium itself [47]. Regarding the effect of calcium and vitamin D on bone metabolism, as well as weight loss, numerous studies have been published and the discussion is beyond the scope of this article. For more in-depth view, please see the discussion in [21]. The prevalence of OSA was not reported in this weight loss study. The participants (although all with overweight/obesity by inclusion criteria) only suffered from osteopenia and mild muscle loss and probably only had pre-OSA phenotype. Therefore, these participants, in addition to being younger, were in a relatively better shape compared with the participants of other studies, where those with more deteriorated body composition were recruited. There was a considerable attrition rate as well as missing data points in this study -- otherwise typical for longitudinal intervention studies -- which were counteracted by statistical manipulations. Nevertheless, such kind of studies are valuable in revealing important correlational and causal relations, especially that it was conducted in the Caucasian early- postmenopausal women with overweight/obesity -- which increased the homogeneity -- particularly regarding the bone and body composition that are different among different ethnic and sex groups (e.g., Caucasian vs. African Americans or women vs. men).

Cervo et al. study [23], investigating the relation between the E-DII and body composition, was included in this review although OSA was not presented as such, and it was not possible to calculate the prevalence from the presented data. However, the BMD and changes in T-scores were given, along with the number of fractures and fall risks to account for the bone outcomes. Additionally, handgrip strength was low for both women and men, and so were some other lean/muscle tissue measures, and all participants had overweight/obesity based on the total percent of body fat measured by DXA. Therefore, it could be assumed that most of the participants had pre- or full-OSA phenotypes. Additionally, this was a prospective study with a considerable number of participants followed at 5 and 10 years and several important variables measured/assessed. However, the E-DII scores were based on only 19 nutrients, compared to other studies where 27-48 nutrients were used [48]. The E-DII scores also had relatively narrow range, possibly weakening statistical analyses. The results indicating the association of higher proinflammatory diet with reduced BMD in both women and men, but increased fracture incidence and risk of falls only in men (and decreased in women), are quite intriguing and should be investigated in a more specific way to elucidate these puzzling findings.

The studies conducted in Korea and published by the same group of authors [16–18], have several limitations, and some were addressed by the authors. For example, in one study [16] the participants were divided into 8 groups and due to the discrepancy in the distribution of women/men and number of participants within the groups, both women and men were combined for analysis. The intake of supplements was not considered when assessing the intake of calcium and phosphorus, because the focus was on the dietary intake (as per authors' statement). However, this study had enough participants to classify them into 8 distinct groups according to OSA components—the normal group, single component groups, the groups with two OSA components, and the OSA group, thus providing comparison among each and pointing out to the characteristics of the OSA group. This approach seems to be missing in some other studies, due to either smaller number of participants and/or just non-inclusion of the comparison of OSA with other groups [13–15,17,20,21,23]. For example, in another study [17] the authors compared participants with OSO with only those having normal body composition, thus some possible relationships and comparisons with participants in other groups (e.g., osteopenia, osteopenic obesity or sarcopenia, sarcopenic obesity) in relation to protein intake were not assessed. Additionally, although the authors did not directly report the prevalence of OSO, it could be calculated from the data presented. Accordingly, 649 out of 706 women (91.9%) and 216 out of 645 men (33.4%) were characterized as having OSO [17]. Such high prevalence in women and discrepancy between women and men was not noted in other studies. It could be because women with OSO were significantly older than men with OSO and already had undergone through postmenopausal bone and muscle loss and fat accumulation, otherwise not occurring this early and this drastically in men [9]. Also, the reported prevalence of OSO in Choi et al. [17] study was much higher than the prevalence reported in their subsequent study [16] (discussed above), although the same criteria for osteopenia/osteoporosis and obesity were used and the study was conducted in similar population (KNHANES 2008-2011 and 2008-2009, respectively). Unfortunately, this discrepancy was not addressed in their subsequent study [16] and it is hard to speculate further. Regarding the last of these three studies [18], it was conducted only in women and although the DXA scans were utilized for bone and lean tissue assessment, the waist circumference (≥ 85 cm) as a cutoff for obesity was used, thus making it harder to compare with the studies where DXA or BIA instruments were used. However, the reported prevalence of OSO of 13.7% is more in line with that reported in other studies within community dwelling populations. Although all three mentioned studies [16–18] were conducted by the same group of researchers, utilizing the KHNAES data bases, they revealed quite different prevalence of OSA/OSO (see Table 1) which was not addressed/discussed by the authors.

The two other studies Kim et al., and Park et al., [13,20] also analyzed the KNHANES data base (2008-2010 and 2009-2011, respectively), investigating the association of the DII and DQI-I, respectively, with OSO prevalence/characteristics. For example, in the Park et al. [20] study the participants (only females) were classified based on body composition determined by BMI. The

limitations of defining overweight/obesity by BMI has been addressed numerous times [2–4]. It is hard to justify in this case, since DXA was available and used for bone and lean mass assessment. On the upside, the authors used Asia–Pacific guidelines for BMI classifications [49,50] with values for normal weight $18.5 \text{ kg/m}^2 \leq \text{BMI} < 23 \text{ kg/m}^2$, overweight $23 \text{ kg/m}^2 \leq \text{BMI} < 25 \text{ kg/m}^2$, and obesity $\text{BMI} > 25 \text{ kg/m}^2$. Despite these limitations, this study analyzed the relationship between OSO and DII using the large KNHANES data base and the results seem to be meaningful as the data may be representative of postmenopausal Korean women. In the Kim et al., [13] study, the association of DQI-I scores with other combinations of abnormal body composition could not be analyzed due to insufficient sample size in other groups. Therefore, the comparison was done with the healthy Korean young adults. Another drawback was that they defined obesity as “top 40% of body fat by gender” (as stated in the paper). It is not clear whether they used $\geq 40\%$ body fat for both women and men, which would be quite high if used for men. So again, hard to derive some comparable OSA prevalence value.

The major drawback de Franca et al., study [19] was that some study groups comprised very small number of participant (between six and eleven). Despite this, we decided to include this study in this review because it measured important outcome variables: diet, muscle strength, functional performance and sedentary lifestyle in relation to body composition and compared OSO participants with those in normal and all others with impaired body composition, although that could be considered as both advantage and disadvantage (considering the small sample sizes in some groups).

Overall, it is encouraging to find several studies addressing the complex entity such as OSA and reporting some promising relations with certain nutrients, including protein, calcium, potassium, vitamins D and C, as well as higher low-fat dairy foods and fruit intake (both reflecting higher diet quality foods). Weaker relations, yet important were found with omega-3, fiber, magnesium, phosphorus, and vitamin K.

4.2. Serum nutritional biomarkers and OSA/OSO

Table 2 presents studies examining some of the nutritional biomarkers related to body composition and OSO. In view that one of the future hot topics in this area is finding the metabolic profile of OSA/OSO [10], these studies, although limited, are at the forefront research.

As it is well established, iron overload can promote oxidative stress and cellular membrane damage by generating reactive oxygen species, particularly risky for older men and postmenopausal women [51]. Higher iron intake or elevated serum ferritin levels are associated with impaired body composition [52,53]. Some studies reported that iron accumulation in older population could impair bone and muscle metabolism and fat accumulation [54], possibly due to proinflammatory environment and disturbance of both bone and muscle metabolic pathways. The findings from the Chung et. a., study [26] showed that women in the highest serum ferritin tertile had significantly worse body composition outcomes, including the highest prevalence of OSO, despite that the overall prevalence of OSO in women was lower than that in men (6.4% vs. 9.4%). It is not quite clear why the association of ferritin and OSO (or other impaired body composition components) did not apply to men, despite that the women with OSO were younger than men (66.3 vs. 67.7 years). One of the reasons could have been the classification of participants for both sarcopenia and obesity by using the cutoff values applicable for the Western population. It has been reported that individuals of Asian ethnicity have 3–5% higher body fat for the same BMI values [49]. Therefore, some men might have been missed in the OSO categorization. Nevertheless, this is an interesting and unique study, and the findings could stimulate emphasis on iron intake/overload and body composition in older age and even contribute to developing biomarkers for OSO identification, as suggested by authors [26].

Vitamin D (in its various serum metabolites; calcidiol, calcitriol) is involved in the crosstalk between bone and skeletal muscle by stimulating the production of bone- and muscle-derived factors such as osteocalcin, osteopontin, sclerostin, and myostatin, as well as vascular endothelial growth factor and insulin growth factor, that all act as endocrine signals between the two tissues. Similarly, low calcidiol (25(OH)D) in obese individuals is still a conundrum as to what the cause and effect is, in view that adipose tissue scavenges much of the circulating calcidiol, but it also provides the source

for it [10]. In addition to regulating many metabolic pathways as well as immune response, it is obvious that vitamin D deficiency could have serious impact on body composition outcomes [55]. While there are numerous studies investigating serum vitamin D inadequacy with various body composition components, so far only three have been done in individuals with OSO [27–29]. The results of all three studies revealed the supporting role of calcidiol in offsetting the pathogenesis of the condition. Two studies [28,29] have been derived from the KNHANES in women and men >50 years and showed that higher serum calcidiol was associated with significantly lower odds of having adverse body composition features, especially OSO, in both sexes. The problem with the Kim et al., [29] study is that the cutoff for adiposity/obesity was not clearly explained (“in the upper 40% body fat for both sexes”) as addressed above in discussing another article from those authors [13]. This was probably the reason for much higher OSO prevalence and obesity rates in women compared to men (most of them could have been missed). A newer analysis from another group investigating the clinical manifestations associated with OSO [28] using KNHANES confirmed that vitamin D deficiency/inadequacy was significantly higher in both women and men with OSO compared to those with osteopenic obesity, sarcopenic obesity or obesity-only. Neither of the studies controlled for sun exposure, seasonal variations or vitamin D supplements, though. These two studies used the same population data-base (KNHANES IV and V) and the results revealed the same outcomes regarding the relationship between serum vitamin D status and OSO condition. However, the OSO prevalence in the study from 2019 [28] was almost double that of the study from 2017 [29]. The criteria for osteopenia/osteoporosis, sarcopenia and adiposity in the newer study [28] were more refined, or at least better explained. In the earlier study [29], the ALM was not corrected for weight and cutoff for obesity was 40% which could have missed many individuals, particularly men (Table 2). Moreover, although in both studies the inclusion and exclusion criteria were applied, the study from 2019 [28] had more restricted ones and enrolled lower number of subjects.

Among the reviewed/published studies, there were no interventional clinical trials which, although smaller in sample size, are controlled and focused, thus could provide more reliable data and cause-and-effect relations. Of the biomarkers, only serum 25(OH)D and ferritin were studied showing strong relations with OSA, positive and adverse, respectively. Of note is that all the results/analyses from the studies conducted in Korea, were extrapolated from the Korean National Databases (KNHANES) with considerable number of participants providing the epidemiological angle to the issue of OSA/OSO.

4.3. Physical Activity and OSA

Recently, a meta-analysis [12] was conducted on four randomized interventional trials included also in this review [30,31,34,35] with resistance/aerobic exercise in OSA/OSO participants, showing improvement in various outcome measures. Interestingly, both Lee et al., and Shen et al. [30,35] reported improvement in BMD and the former was the only study with a 6-month follow-up revealing unfortunately, no maintenance of the gained benefits. Both studies had a very small sample size (about $n = 15$ in intervention and control groups), although there were no dropouts and compliance was good. The improvements in BMD assessed by DXA was noted already after 12 weeks of intervention. However, it is worth noting that the typical change in BMD (without medications or some drastic health deterioration) measured by DXA could be noted only between 5-6 months, due to the smaller biological/structural changes in BMD in proportion to the instrument's errors [56]. It is possible that the exercise regimen in the above two studies was very efficient, particularly in the study by Shen et al., [35] where both resistance and aerobic training were employed. Nevertheless, the interpretation of these results should be taken with caution.

The study by Cunha et al., [31] is interesting as the authors were the first ones to utilize a composite Z-score to identify participants with better or worse body composition as an alternative to diagnosing OSO. The composite Z-score was derived from average of the muscular strength, skeletal muscle mass (SMM), % body fat, and BMD, and calculated by formula: (muscular strength Z-score) + (SMM Z-score) + (-1 × body fat Z-score) + (BMD Z-score) / 4. The changes induced by the resistance training were evaluated based on the percent change in a composite Z-score. The results also revealed

that the three sets of exercise induced better response compared to one set, and significantly so compared to the control group.

All papers by the Iranian group evaluated here, described the same 12-week resistance training with elastic band but analyzed different outcome measures [32–34,36,37] (see Table 3, bottom rows). This was a well-designed and executed intervention in $n = 63$ women with OSA/OSO. While it is commendable to take advantage of the costly studies in human subjects and use the data to examine different outcomes, in this case the methodology and intervention descriptions were repeated in all papers as well as some of the results (e.g., anthropometry, body composition). Additionally, numerous bone, muscle and functional performance parameters were measured and reported in each paper, and it was not always clear which ones were used to classify women with OSA/OSO (e.g., composite Z scores or regular cutoffs for each tissue), or functional performance measures for sarcopenia. Nevertheless, these are important findings and in some of the authors' more recent papers the distinctive and novel markers were evaluated, like serum microRNAs (miR-133 and miR-206), although no change with exercise was found [32]. microRNAs are small, non-coding RNAs involved in the regulation of some physiological and pathological processes, including cell proliferation, apoptosis, and differentiation. It was reported previously that they promoted the osteogenic differentiation after osteoporotic fractures [57]. Therefore, the researchers hypothesized that some microRNAs (namely, 133, 206) could be involved in muscle-bone communication and possible transport of positive signals (e.g., induced by exercise) to other tissues. Although a novel idea, the employed exercise regimen did not induce such an effect and there was no change in these microRNAs expressions after the intervention. Another microRNA (miR-146) is known to increase vascular aging by reducing Sirtuin 1 (SIRT1) and activating nuclear factor kappa B (NF- κ B) which both promote vascular smooth muscle cells apoptosis [58]. In their other study [36], the researchers examined the change in miR-146 with resistance training and reported its decreased expression induced by exercise and associated improvements in LDL and HDL. Another paper reported the improvements in some cardiometabolic risk factors, both traditional and composite (e.g., lipid-accumulation product, triglyceride-glucose-BMI index, visceral adiposity index, atherogenic index of plasma, Framingham risk score) with the exercise regimen [33]. Additionally, Kazempour et al. [37] (from the same group), used the smaller sample ($n = 48$; 26 and 22 in intervention and control groups, respectively) and analyzed some additional markers, including insulin growth factor (IGF-2), and fibroblast growth factor (FGF-2), showing improvement with exercise in both, see Table 3. (To avoid repeating the same design/intervention for each study in Table 3, they are listed under the Banitalebi et al., [34], with the outcome measures for each noted in the last column).

Overall, the number of studies with exercise intervention is very limited and yet, these are the only interventional studies with OSA/OSO participants. Additionally, all studies (except one) were done in women, and all (except one) employed resistance training, mostly with elastic bands. The studies had relatively small sample size and the intervention time was short (12 weeks), which may have impacted the accuracy of the calculations and ultimately the interpretation of the results. However, there were no serious side effects and the compliance with exercise was good in all studies, deeming them safe and efficient for improvements of OSA/OSO components in older individuals. Therefore, future studies with larger number and more diverse participants, longer duration of intervention, as well as different exercise modes are needed to verify these results, contribute to the overall database, and better understanding of this complex syndrome.

5. Summary and Conclusions

In this scoping review, 23 eligible studies, investigating nutritional and physical activity modulators associated with OSA/OSO were evaluated and discussed. OSA syndrome is a complex entity, involving the simultaneous impairment of all three body composition tissues (bone, muscle, adipose) with multifaceted etiology and causes, mostly related to the inevitable aging processes. Although OSA has been identified relatively recently, the research is picking up and numerous studies have been conducted, although not all had the elements required for inclusion in this review. This was particularly a case for the older studies where each of the body composition component was

studied separately or at the most as a combination of two impaired conditions (e.g., sarcopenic obesity) [1]. Additionally, in some instances where all three body composition components were included/studied, it was not always possible to connect them simultaneously to derive OSA/OSO and relate to the independent/exposure variables; in this case nutrition, serum nutritional biomarkers, and physical activity. Nevertheless, this review revealed some important findings contributing to a better understanding of the OSA syndrome in older individuals (particularly women), providing empirical data for the theoretical hypotheses.

The most important findings regarding the nutrients/dietary intake and OSA revealed that higher protein, calcium, potassium, and vitamins D and C intakes, in addition to consuming enough of fruit and low-fat dairy foods -- comprising antioxidative nutrients (fruits) and food of high nutritional quality (both) -- emerged as most beneficial. Some other nutrients, although to a lesser extent, appeared important and in line with our previous recommendations [7,8,10]. These include omega-3 polyunsaturated fatty acids, fiber, magnesium, and vitamin K. No interventional or clinical trials were conducted to investigate serum biomarkers and determine the metabolic profile of OSA, which currently is a much sought of and needed research. Among four studies, three showed beneficial association of higher serum 25(OH)D and OSA and one (quite new and surprising) showed higher serum ferritin levels being associated with worsened OSA outcomes. Several studies reported benefits of recreational activities and less sedentary lifestyle on OSA, however, the promising were the interventional studies with resistance training, all conducted in women with OSA. Among the most beneficial outcomes were the improvements in body composition (body fat, muscle), most of the functional performance measures and some of the biomarkers (mostly cardiovascular). Therefore, based on the reviewed studies, a nutrient-dense food with plenty of protein, calcium and vitamins D and C along with an active lifestyle and possibly some organized and safe exercise, like resistance training, would be beneficial to maintain good body composition and managing OSA. Additionally, multi-component interventions, targeting each distinct component of OSA, are likely to benefit older adults with overweight/obesity and poor bone and muscle health. We and others have proposed lifestyle approaches for musculoskeletal health in these individuals which incorporate a combination of dietary/energy restriction, with adequate intakes of protein, calcium and vitamin D, and also progressive resistance training and weight-bearing impact exercise to offset and potentially reverse weight loss-associated declines in bone and muscle mass [6,7,59]. This type of diet and exercise regimen is beneficial for overall health, especially in aging population [60,61].

6. Existing Problems and Recommendations for Future Studies

The operational definitions and diagnostic criteria are already available for osteopenia/osteoporosis [41] and sarcopenia [42] and to some extent for sarcopenic obesity. For the latter, a consensus statement was just revised and published last year with the updated definition of sarcopenic obesity, its diagnostic criteria to include both gold-standards and other acceptable alternates, as well as methodologies to be used with the related cutoffs [43]. Unfortunately, substantial incongruity exists on standardized cut-points for body fat percentage to define obesity and even more so for visceral adiposity. This is due to numerous reasons (e.g., adipose tissue heterogeneity, demographic factors such as age and ethnicity) as was discussed recently [2]. Additionally, based on the OSA definition, it is not just the amount of fat tissue (as overt overweight/obesity), but also the kind of fat (visceral, subcutaneous) and infiltrated fat into the bone and muscle which creates the problems, as the latter two are not easily measured and detected [2]. As we proposed earlier [7], some other measures, including waist circumference, may be used in place of body fat percentage, or as an additional measure to identify adults with visceral adiposity, especially if more advanced technology (iDXA, CT) is not available. Therefore, identifying OSA still depends on each researcher's abilities, institutional infrastructure and available equipment.

It is clear that the lack of universally established diagnostic criteria for OSA/OSO hinder patients' identification, worldwide determination of its prevalence, assessment of related outcomes, as well as the creation of any public health policies. Even more importantly, the inability to properly identify OSA/OSO patients impedes the development for its prevention and treatment strategies. This very

review exposed some of the marked discrepancies; namely, different diagnostic approaches which originate from different criteria used for classifications of obesity and sarcopenia, methods to assess functional abilities, as well as differently applied reference values for the variables examined and statistical stratification. Once when the consensus on definition and diagnostic criteria is established, the evaluation of patients for OSA/OSO should become a part of the routine clinical practice.

Under the broader umbrella and based on the evidence presented, it is obvious that large observational, longitudinal, and interventional (in form of the randomized controlled trials) studies are needed to further elucidate the distinct as well as the synergistic effects of nutritional and/or exercise roles in individuals with OSA. The intervention should have a specific focus on the OSA physical phenotype and on the metabolic and inflammatory biomarkers. This will enable the clarification of the role of specific nutrients and/or exercise regimen, in the pathogenesis, management, and treatment of OSA. In this context, the prospective studies and the secondary analysis of existing datasets (the cheapest) to study the possible predictors and clinical impact would be of a great value.

Besides examining nutrition and physical activity in relation with OSA, a lot more is needed in this area, including, but not limited to:

- The participants with OSA should be compared with those having osteopenia/osteoporosis, osteopenic adiposity, sarcopenia, sarcopenic adiposity, osteopenic sarcopenia, adiposity-alone or normal-body composition parameters (see Figure 1 for the combination of conditions). This will provide a clearer picture about OSA itself and all the differences between other body composition impairments.
- Individuals of different sex (as of now, women are studied more frequently than men), age, and race/ethnicities (e.g., there are no studies in African Americans), as well as critical populations (like nursing home residents), are needed to better define the diagnostic criteria, and to elucidate OSA. While majority of the studies have been done in older population, equally important would be the studies in younger individuals, as the earlier work identified prevalent OSA phenotype in healthy, young, obese individuals [62].
- The potential breakthrough could be the development of biomarkers for each tissue which in combination may indicate the existing impairments and presence of OSA. A pilot study showed increased levels of serum sclerostin (bone resorption marker), skeletal muscle troponin (muscle breakdown marker), and inferior lipid profile and increased leptin in women with OSA compared to their counterparts with only one or two impaired body composition components [63]. However, more refinement is necessary, and the series of omics will need to be determined to serve as potential biomarkers.
- Likewise, in view of the swift technological advances, such as genomic sequencing and molecular targeted drug exploitation, the concept of precision medicine can be used to demarcate OSA using multiple data sources from genomics to digital health metrics, to artificial intelligence in order to facilitate an individualized yet “evidence-based” decisions regarding diagnostic and therapeutic approaches. In this way, therapeutics can be centered toward patients based on their molecular presentation rather than grouping them into broad categories with a “one size fits all” approach.

Author Contributions: Conceptualization, J.Z.I., V.V., D.R.M., and N.V.; search strategy, J.Z.I., V.V., and D.R.M.; independently reviewed abstracts and papers, A.A., D.R.M., S.P., M.P.; and V.V.; final selection of relevant papers, J.Z.I.; writing, original draft preparation, J.Z.I. and A.A.; visualization, M.P. and S.P., writing, reviewing and editing, J.Z.I., and D.R.M.; supervision, V.V. All authors have read and agreed to the published version of the manuscript.

Funding: Not applicable

Institutional Review Board Statement: Not applicable

Informed Consent Statement: Not applicable

Data Availability Statement: Not applicable

Acknowledgments: This work is part of the Fulbright Scholar Award Project at the University of Belgrade, Serbia: PS00338126, U.S. Department of State Bureau of Education and Cultural Affairs, 2022-2023 academic year (JZI).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Ilich, J.Z.; Kelly, O.J.; Inglis, J.E.; Panton, L.B.; Duque, G.; Ormsbee, M.J. Interrelationship among muscle, fat, and bone: connecting the dots on cellular, hormonal, and whole body levels. *Ageing Res. Rev.* **2014**, *15*, 51–60, doi:10.1016/j.arr.2014.02.007.
2. Ilich, J.Z.; Gilman, J.C.; Cvijetic, S.; Boschiero, D. Chronic Stress Contributes to Osteosarcopenic Adiposity via Inflammation and Immune Modulation: The Case for More Precise Nutritional Investigation. *Nutrients* **2020**, *12*, doi:10.3390/nu12040989.
3. Donini, L.M.; Pinto, A.; Giusti, A.M.; Lenzi, A.; Poggiogalle, E. Obesity or BMI Paradox? Beneath the Tip of the Iceberg. *Front. Nutr.* **2020**, *7*, 53, doi:10.3389/fnut.2020.00053.
4. Scott, D.; Johansson, J.; Ebeling, P.R.; Nordstrom, P.; Nordstrom, A. Adiposity Without Obesity: Associations with Osteoporosis, Sarcopenia, and Falls in the Healthy Ageing Initiative Cohort Study. *Obesity (Silver Spring)*. **2020**, *28*, 2232–2241, doi:10.1002/oby.22984.
5. Arsic, A.; Takic, M.; Kojadinovic, M.; Petrovic, S.; Paunovic, M.; Vucic, V.; Ristic Medic, D. Metabolically healthy obesity: is there a link with polyunsaturated fatty acid intake and status? *Can. J. Physiol. Pharmacol.* **2021**, *99*, 64–71, doi:10.1139/cjpp-2020-0317.
6. Ilich, J.Z.; Kelly, O.J.; Inglis, J.E. Osteosarcopenic Obesity Syndrome: What Is It and How Can It Be Identified and Diagnosed? *Curr. Gerontol. Geriatr. Res.* **2016**, *2016*, 7325973, doi:10.1155/2016/7325973.
7. Kelly, O.J.; Gilman, J.C.; Boschiero, D.; Ilich, J.Z. Osteosarcopenic Obesity: Current Knowledge, Revised Identification Criteria and Treatment Principles. *Nutrients* **2019**, *11*, doi:10.3390/nu11040747.
8. Ilich, J.Z. Nutritional and Behavioral Approaches to Body Composition and Low-Grade Chronic Inflammation Management for Older Adults in the Ordinary and COVID-19 Times. *Nutrients* **2020**, *12*, doi:10.3390/nu12123898.
9. JafariNasabian, P.; Inglis, J.E.; Reilly, W.; Kelly, O.J.; Ilich, J.Z. Aging human body: changes in bone, muscle and body fat with consequent changes in nutrient intake. *J. Endocrinol.* **2017**, *234*, R37–R51, doi:10.1530/JOE-16-0603.
10. Ilich, J.Z. Osteosarcopenic adiposity syndrome update and the role of associated minerals and vitamins. *Proc. Nutr. Soc.* **2021**, *80*, 344–355, doi:10.1017/S0029665121000586.
11. Kelly, O.J.; Gilman, J.C. Can Unconventional Exercise be Helpful in the Treatment, Management and Prevention of Osteosarcopenic Obesity? *Curr. Aging Sci.* **2017**, *10*, 106–121, doi:10.2174/1874609809666160509122725.
12. Yang, J.-M.; Ye, H.; Zhu, Q.; Zhang, J.-H.; Liu, Q.-Q.; Xie, H.-Y.; Long, Y.; Huang, H.; Niu, Y.-L.; Luo, Y.; et al. Effects of resistance training on body composition and physical function in elderly patients with osteosarcopenic obesity: a systematic review and meta-analysis. *Arch. Osteoporos.* **2022**, *17*, 82, doi:10.1007/s11657-022-01120-x.
13. Kim, J.; Lee, Y.; Kye, S.; Chung, Y.-S.; Kim, J.-H.; Chon, D.; Lee, K.E. Diet quality and osteosarcopenic obesity in community-dwelling adults 50 years and older. *Maturitas* **2017**, *104*, 73–79, doi:10.1016/j.maturitas.2017.08.007.
14. Cvijetić, S.; Keser, I.; Boschiero, D.; Ilich, J.Z. Osteosarcopenic Adiposity and Nutritional Status in Older Nursing Home Residents during the COVID-19 Pandemic. *Nutrients* **2023**, *15*, doi:10.3390/nu15010227.
15. Keser, I.; Cvijetić, S.; Ilić, A.; Colić Barić, I.; Boschiero, D.; Ilich, J.Z. Assessment of Body Composition and Dietary Intake in Nursing-Home Residents: Could Lessons Learned from the COVID-19 Pandemic Be Used to Prevent Future Casualties in Older Individuals? *Nutrients* **2021**, *13*, doi:10.3390/nu13051510.
16. Choi, M.-K.; Bae, Y.-J. Dietary calcium, phosphorus, and osteosarcopenic adiposity in Korean adults aged 50 years and older. *Arch. Osteoporos.* **2021**, *16*, 89, doi:10.1007/s11657-021-00961-2.
17. Choi MK, Bae YJ. Protein intake and osteosarcopenic adiposity in Korean adults aged 50 years and older. *Osteoporos Int.* **2020** *31*, 2363–2372. doi: 10.1007/s00198-020-05529-3
18. Bae, Y.-J. Fruit intake and osteosarcopenic obesity in Korean postmenopausal women aged 50–64 years. *Maturitas* **2020**, *134*, 41–46, doi:10.1016/j.maturitas.2020.02.003
19. de França, N.A.G.; Peters, B.S.E.; dos Santos, E.A.; Lima, M.M.S.; Fisberg, R.M.; Martini, L.A. Obesity Associated with Low Lean Mass and Low Bone Density Has Higher Impact on General Health in Middle-Aged and Older Adults. *J. Obes.* **2020**, *2020*, 8359616, doi:10.1155/2020/8359616.

20. Park, S.; Na, W.; Sohn, C. Relationship between osteosarcopenic obesity and dietary inflammatory index in postmenopausal Korean women: 2009 to 2011 Korea National Health and Nutrition Examination Surveys. *J. Clin. Biochem. Nutr.* **2018**, *63*, 211–216, doi:10.3164/jcbtn.18-10.
21. Ilich, J.Z.; Kelly, O.J.; Liu, P.-Y.; Shin, H.; Kim, Y.; Chi, Y.; Wickrama, K.K.A.S.; Colic-Baric, I. Role of Calcium and Low-Fat Dairy Foods in Weight-Loss Outcomes Revisited: Results from the Randomized Trial of Effects on Bone and Body Composition in Overweight/Obese Postmenopausal Women. *Nutrients* **2019**, *11*, doi:10.3390/nu11051157.
22. Ilich, J.Z.; Liu, P.-Y.; Shin, H.; Kim, Y.; Chi, Y. Cardiometabolic Indices after Weight Loss with Calcium or Dairy Foods: Secondary Analyses from a Randomized Trial with Overweight/Obese Postmenopausal Women. *Nutrients* **2022**, *14*, doi:10.3390/nu14051082.
23. Cervo, M.M.; Shivappa, N.; Hebert, J.R.; Oddy, W.H.; Winzenberg, T.; Balogun, S.; Wu, F.; Ebeling, P.; Aitken, D.; Jones, G.; et al. Longitudinal associations between dietary inflammatory index and musculoskeletal health in community-dwelling older adults. *Clin. Nutr.* **2020**, *39*, 516–523, doi:10.1016/j.clnu.2019.02.031
24. European Food Safety Authority. Nutrient Recommendations: Dietary Reference Values (DRV). Available online: <https://www.efsa.europa.eu/en/interactive-pages/drvs>.
25. Nutrient Recommendations: Dietary Reference Intakes (DRI). Available online: https://ods.od.nih.gov/HealthInformation/Dietary_Reference_Intakes.aspx.
26. Chung, S.-J.; Lim, H.S.; Lee, M.-Y.; Lee, Y.-T.; Yoon, K.J.; Park, C.-H. Sex-Specific Associations between Serum Ferritin and Osteosarcopenic Obesity in Adults Aged over 50 Years. *Nutrients* **2022**, *14*, doi:10.3390/nu14194023.
27. Ma, Y.; Yuyan, L.; Shen, Z.; Lu, C.; Yu, He.; Shuai, X.; Hong, L.; Feng, Chen.; Jie Gao, D.W. Association of Serum 25-(OH)-D3 with Osteosarcopenic Obesity: A Cross-Sectional Study of Older Chinese. *Res. Sq.* **2020**, <https://doi.org/10.21203/rs.3.rs-84790/v1>
28. Kim, Y.M.; Kim, S.; Won, Y.J.; Kim, S.H. Clinical Manifestations and Factors Associated with Osteosarcopenic Obesity syndrome: A Cross-Sectional Study in Koreans with Obesity. *Calcif. Tissue Int.* **2019**, *105*, 77–88, doi:10.1007/s00223-019-00551-y.
29. Kim, J.; Lee, Y.; Kye, S.; Chung, Y.-S.; Lee, O. Association of serum vitamin D with osteosarcopenic obesity: Korea National Health and Nutrition Examination Survey 2008–2010. *J. Cachexia. Sarcopenia Muscle* **2017**, *8*, 259–266, doi:10.1002/jcsm.12154.
30. Lee, Y.-H.; Lee, P.-H.; Lin, L.-F.; Liao, C.-D.; Liou, T.-H.; Huang, S.-W. Effects of progressive elastic band resistance exercise for aged osteosarcopenic adiposity women. *Exp. Gerontol.* **2021**, *147*, 111272, doi:10.1016/j.exger.2021.111272
31. Cunha, P.M.; Ribeiro, A.S.; Tomeleri, C.M.; Schoenfeld, B.J.; Silva, A.M.; Souza, M.F.; Nascimento, M.A.; Sardinha, L.B.; Cyrino, E.S. The effects of resistance training volume on osteosarcopenic obesity in older women. *J. Sports Sci.* **2018**, *36*, 1564–1571, doi:10.1080/02640414.2017.1403413.
32. Banitalebi, E.; Ghahfarokhi, M.M.; Dehghan, M. Effect of 12-weeks elastic band resistance training on MyomiRs and osteoporosis markers in elderly women with Osteosarcopenic obesity: a randomized controlled trial. *BMC Geriatr.* **2021**, *21*, 433, doi:10.1186/s12877-021-02374-9.
33. Banitalebi, E.; Banitalebi, E.; Ghahfarokhi, M.M.; Rahimi, M.; Laher, I.; Davison, K. Resistance Band Exercise: An Effective Strategy to Reverse Cardiometabolic Disorders in Women With Osteosarcopenic Obesity. *J. Aging Phys. Act.* **2023**, 1–9, doi:10.1123/japa.2022-0241.
34. Banitalebi, E.; Faramarzi, M.; Ghahfarokhi, M.M.; SavariNikoo, F.; Soltani, N.; Bahramzadeh, A. Osteosarcopenic obesity markers following elastic band resistance training: A randomized controlled trial. *Exp. Gerontol.* **2020**, *135*, 110884, doi:10.1016/j.exger.2020.110884
35. Shen, L.; Huang, L.; Wang, L.; Chen, Y.; Li, L.; Zhang, L.; Cao, L.; Liu, C.; Wang, J.; Y.S. Effects of 12 weeks aerobic exercise combined with high speed strength training on old adults with osteosarcopenic obesity syndrome. *Chinese J. Rehabil. Med.* **2020**, *35*, 420–426.
36. Hashemi, A.; Soori, R.; Banitalebi, E.; Choobineh, S. The Effect of Elastic Resistance Bands Training on Vascular Aging Related Serum microRNA-146 Expression and Atherosclerosis Risk Factors in Elderly Women with Osteosarcopenic Obesity: A Randomized Clinical Trial. *Iran. J. Diabetes Obes.* **2020**, *12*, doi.org/10.18502/ijdo.v12i4.5178.
37. Kazemipour, N.; Faramarzi, Mohammad Banitalebi, E. The Effect of 12 Weeks of Theraband Resistance Training on IGF-1 and FGF-2 Levels and Their Relationships with Myokines on Bone Mineral Density of Osteosarcopenic Obese Women. *Jentashapir J. Cell. Mol. Biol.* **2022**, *13*, e130641., doi.org/10.5812/jcmb-130641.
38. López-Otín, C.; Blasco, M.A.; Partridge, L.; Serrano, M.; Kroemer, G. The hallmarks of aging. *Cell* **2013**, *153*, 1194–1217, doi:10.1016/j.cell.2013.05.039.

39. Schmauck-Medina, T.; Molière, A.; Lautrup, S.; Zhang, J.; Chlopicki, S.; Madsen, H.B.; Cao, S.; Soendenbroe, C.; Mansell, E.; Vestergaard, M.B.; et al. New hallmarks of ageing: a 2022 Copenhagen ageing meeting summary. *Ageing (Albany, NY)*. **2022**, *14*, 6829–6839, doi:10.18632/aging.204248.
40. WHO <https://www.who.int/news-room/fact-sheets/detail/ageing-and-health>.
41. Kanis, J.A. Diagnosis of osteoporosis and assessment of fracture risk. *Lancet (London, England)* **2002**, *359*, 1929–1936, doi:10.1016/S0140-6736(02)08761-5.
42. Cruz-Jentoft, A.J.; Bahat, G.; Bauer, J.; Boirie, Y.; Bruyère, O.; Cederholm, T.; Cooper, C.; Landi, F.; Rolland, Y.; Sayer, A.A.; Schneider, S.M.; Sieber, C.C.; Topinkova, E.; Vandewoude, M.; Visser, M.; Zamboni, M. Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing*. **2019** *48*, 601. doi: 10.1093/ageing/afz046. Erratum for: *Age Ageing*. **2019** *48*, 16–31. PMID: 31081853; PMCID: PMC6593317.
43. Donini, L.M.; Busetto, L.; Bischoff, S.C.; Cederholm, T.; Ballesteros-Pomar, M.D.; Batsis, J.A.; Bauer, J.M.; Boirie, Y.; Cruz-Jentoft, A.J.; Dicker, D.; et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. *Clin. Nutr.* **2022**, *41*, 990–1000, doi:10.1016/j.clnu.2021.11.014
44. Madeira, T.; Peixoto-Plácido, C.; Sousa-Santos, N.; Santos, O.; Alarcão, V.; Goulão, B.; Mendonça, N.; Nicola, P.J.; Yngve, A.; Bye, A.; et al. Malnutrition among older adults living in Portuguese nursing homes: the PEN-3S study. *Public Health Nutr.* **2018**, 1–12, doi:10.1017/S1368980018002318.
45. Pauly, L.; Stehle, P.; Volkert, D. Nutritional situation of elderly nursing home residents. *Z. Gerontol. Geriatr.* **2007**, *40*, 3–12, doi:10.1007/s00391-007-0430-x.
46. Courtois-Amiot, P.; Allart, H.; de Cathelineau, C.; Legué, C.; Eischen, P.; Chetaille, F.; Lepineux, D.; Raynaud-Simon, A.; Sanchez, M. Covid-19 as an Independent Risk Factor for Weight Loss in Older Adults living in Nursing Homes. *Gerontology* **2023**, doi:10.1159/000529357.
47. Thorning, T.K.; Raben, A.; Tholstrup, T.; Soedamah-Muthu, S.S.; Givens, I.; Astrup, A. Milk and dairy products: good or bad for human health? An assessment of the totality of scientific evidence. *Food Nutr. Res.* **2016**, *60*, 32527, doi:10.3402/fnr.v60.32527.
48. Veronese, N.; Stubbs, B.; Koyanagi, A.; Hébert, J.R.; Cooper, C.; Caruso, M.G.; Guglielmi, G.; Reginster, J.Y.; Rizzoli, R.; Maggi, S.; et al. Pro-inflammatory dietary pattern is associated with fractures in women: an eight-year longitudinal cohort study. *Osteoporos Int.* **2018**, *1*:143–151. doi: 10.1007/s00198-017-4251-5.
49. Deurenberg, P.; Deurenberg-Yap, M.; Guricci, S. Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship. *Obes. Rev.* **2002**, *3*, 141–146, doi:10.1046/j.1467-789x.2002.00065.x
50. World Health Organization. Regional Office for the Western Pacific. (2000). The Asia-Pacific perspective: redefining obesity and its treatment. Sydney: Health Communications Australia. <https://apps.who.int/iris/handle/10665/206936>.
51. Arosio, P.; Levi, S. Ferritin, iron homeostasis, and oxidative damage. *Free Radic. Biol. Med.* **2002**, *33*, 457–463, doi:10.1016/s0891-5849(02)00842-0.
52. Hämäläinen, P.; Saltevo, J.; Kautiainen, H.; Mäntyselkä, P.; Vanhala, M. Serum ferritin levels and the development of metabolic syndrome and its components: a 6.5-year follow-up study. *Diabetol. Metab. Syndr.* **2014**, *6*, 114, doi:10.1186/1758-5996-6-114.
53. Harvey, L.J.; Berti, C.; Casgrain, A.; Cetin, I.; Collings, R.; Gurinovic, M.; Hermoso, M.; Hooper, L.; Hurst, R.; Koletzko, B.; et al. EURRECA-Estimating iron requirements for deriving dietary reference values. *Crit. Rev. Food Sci. Nutr.* **2013**, *53*, 1064–1076, doi:10.1080/10408398.2012.742860.
54. Weinberg, E.D. Iron toxicity: new conditions continue to emerge. *Oxid. Med. Cell. Longev.* **2009**, *2*, 107–109, doi:10.4161/oxim.2.2.8162.
55. Di Filippo, L.; De Lorenzo, R.; Giustina, A.; Rovere-Querini, P.; Conte, C. Vitamin D in Osteosarcopenic Obesity. *Nutrients* **2022**, *14*, doi:10.3390/nu14091816.
56. Lewiecki, E.M. Osteoporosis: Clinical Evaluation. **2021**. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Katsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Singer F, Sperling MA, Stratakis CA, Trencle DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. PMID: 25905277.
57. Weilner, S.; Skaliky, S.; Salzer, B.; Keider, V.; Wagner, M.; Hildner, F.; Gabriel, C.; Dovjak, P.; Pietschmann, P.; Grillari-Voglauer, R.; et al. Differentially circulating miRNAs after recent osteoporotic fractures can influence osteogenic differentiation. *Bone* **2015**, *79*, 43–51, doi:10.1016/j.bone.2015.05.027.
58. Cao, J.; Zhang, K.; Zheng, J.; Dong, R. MicroRNA-146a and -21 cooperate to regulate vascular smooth muscle cell proliferation via modulation of the Notch signaling pathway. *Mol. Med. Rep.* **2015**, *11*, 2889–2895, doi:10.3892/mmr.2014.3107.
59. JafariNasabian, P.; Inglis, J.E.; Kelly, O.J.; Ilich, J.Z. Osteosarcopenic obesity in women: impact, prevalence, and management challenges. *Int. J. Womens. Health* **2017**, *9*, 33–42, doi:10.2147/IJWH.S106107.

60. Milošević, M.; Arsić, A.; Cvetković, Z.; Vučić, V. Memorable Food: Fighting Age-Related Neurodegeneration by Precision Nutrition. *Front. Nutr.* **2021**, *8*, 688086, doi:10.3389/fnut.2021.688086.
61. Ristic-Medic, D.; Kovacic, M.; Takic, M.; Arsic, A.; Petrovic, S.; Paunovic, M.; Jovicic, M.; Vucic, V. Calorie-Restricted Mediterranean and Low-Fat Diets Affect Fatty Acid Status in Individuals with Nonalcoholic Fatty Liver Disease. *Nutrients* **2020**, *13*, doi:10.3390/nu13010015.
62. Stefanaki, C.; Peppas, M.; Boschiero, D.; Chrousos, G.P. Healthy overweight/obese youth: early osteosarcopenic obesity features. *Eur. J. Clin. Invest.* **2016**, *46*, 767–778, doi:10.1111/eci.12659.
63. JafariNasabian, P.; Inglis, J.E.; Ave, M.P.; Hall, K.J.; Nieto, S.E.; Kelly, O.J.; Ilich, J.Z. Metabolic Profile of Osteosarcopenic Obesity Syndrome: Identifying Biomarkers for Diagnostic Criteria. *FASEB J.* **2018**.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.